Deep brain stimulation (DBS) is a therapy that has been administered to over 100,000 patients worldwide. The majority of people receiving deep brain stimulation live with a diagnosis of Parkinson’s disease (PD). The technique has been helpful for improving tremor, on-off fluctuations, dyskinesia, and off time. One of the main limitations of deep brain stimulation has been that it requires brain surgery and carries an associated risk of hemorrhage, stroke, infection, and hardware failure.
Should we consider subcutaneous apomorphine infusions for Parkinson’s disease patients who do not want deep brain stimulation or a dopamine pump? There is a growing interest among people with Parkinson’s disease (PD) and families for a “nonsurgical” alternative to deep brain stimulation (DBS) surgery or to Duopa pump therapy. The idea of brain surgery or a feeding tube have been cited as being undesirable for large numbers of PD patients.
Part of Steven Goldenthal’s job is to get people connected. He wants to know how they feel, gets to know their medical history, what medications they take and if they are happy with their Parkinson’s disease (PD) care.
Something resonated with me on my recent visit to the Beth Israel Deaconess Medical Center, a Parkinson’s Foundation Center of Excellence (COE). As I listened to the Parkinson’s patients and caregivers panel, I was impressed to learn that everyone unanimously agreed on the vital importance of team care. From the movement disorder specialist to the nurse, everyone kept referring to “our” care plan. It was working.
Considerable evidence has been mounting in support of a relationship between the gastrointestinal (GI) system and Parkinson’s disease (PD). Many pathologists and neurologists even believe that Parkinson’s may start in the gut, but this view remains speculative. Many GI symptoms, such as constipation, occur as prominent and disabling PD symptoms. In the July 2013 What’s Hot in PD? column, I addressed H.
Who has the highest risk of injury among people with Parkinson’s disease (PD)? Is there a connection between medication combinations and falling less? Are prescription antipsychotics safe? Earlier this year, NPF presented four posters at the World Parkinson Congress (WPC) that answered these questions and more.
Ted Dawson, PhD, and colleagues at the Johns Hopkins University, a National Parkinson Foundation Center of Excellence, have uncovered a potential new approach to treat Parkinson’s disease (PD). Researchers in Dawson’s laboratory focused on a protein called lymphocyte-activation gene 3, known as LAG3. This protein has been shown to be important in cell to cell transfers of α-synuclein (Lewy bodies), which is a protein found in the brain of a person with PD.
While reviewing data from the National Parkinson Foundation’s (NPF) Parkinson’s Outcomes Project a year ago, I noticed a participant whose quality of life went from pretty good to terrible, then back to pretty good. I wondered, “what happened here?” The answer: psychosis.
A recent press release from the National Institutes of Neurological Disorders and Stroke detailed exciting ongoing work aimed to uncover magnetic resonance imaging (MRI) techniques capable of tracking Parkinson’s disease (PD) progression. In this month’s What’s Hot in PD? column we will review the recent progress of MRI-based biomarkers for Parkinson’s diagnosis and progression, and discuss the importance of the findings, especially in the context of clinical trials.
With medical marijuana now legalized in 28 states and Washington, D.C., it is obvious that there is strong interest in its therapeutic properties. Researchers are testing marijuana, which is also called cannabis, as a treatment for many illnesses and diseases, including neurological conditions, with Parkinson's disease (PD) high on the list.